Trinity Biotech PLC Company Profile (NASDAQ:TRIB)

About Trinity Biotech PLC (NASDAQ:TRIB)

Trinity Biotech PLC logoTrinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic & Testing Substances Manufacturers
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TRIB
  • CUSIP: N/A
  • Web:
  • Market Cap: $122.85 million
  • Outstanding Shares: 21,847,000
Average Prices:
  • 50 Day Moving Avg: $5.39
  • 200 Day Moving Avg: $5.58
  • 52 Week Range: $5.09 - $7.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 30.06
  • P/E Growth: 1.26
Sales & Book Value:
  • Annual Revenue: $98.79 million
  • Price / Sales: 1.13
  • Book Value: $4.89 per share
  • Price / Book: 1.04
  • EBITDA: $7.39 million
  • Net Margins: -100.45%
  • Return on Equity: 5.54%
  • Return on Assets: 2.70%
  • Debt-to-Equity Ratio: 0.89%
  • Current Ratio: 5.33%
  • Quick Ratio: 3.88%
  • Average Volume: 40,318 shs.
  • Beta: 1.33
  • Short Ratio: 14.42

Frequently Asked Questions for Trinity Biotech PLC (NASDAQ:TRIB)

What is Trinity Biotech PLC's stock symbol?

Trinity Biotech PLC trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech PLC's earnings last quarter?

Trinity Biotech PLC (NASDAQ:TRIB) posted its earnings results on Thursday, July, 21st. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. The company earned $26.30 million during the quarter, compared to the consensus estimate of $24.30 million. Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. View Trinity Biotech PLC's Earnings History.

When will Trinity Biotech PLC make its next earnings announcement?

Trinity Biotech PLC is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Trinity Biotech PLC.

Who are some of Trinity Biotech PLC's key competitors?

Who are Trinity Biotech PLC's key executives?

Trinity Biotech PLC's management team includes the folowing people:

  • Ronan O'Caoimh, Executive Chairman of the Board
  • Kevin Tansley, Chief Financial Officer, Secretary
  • Rory Nealon, Chief Operating Officer, Executive Director
  • Eric Brouwer Ph.D., Chief Scientific Officer, and Vice President Cardiac
  • James Walsh Ph.D., Executive Director
  • Clinton H. Severson, Non-Executive Director
  • Denis R. Burger Ph.D., Senior Non-Executive Independent Director
  • Peter Coyne, Non-Executive Independent Director
  • James D. Merselis, Non-Executive Independent Director

Who owns Trinity Biotech PLC stock?

Trinity Biotech PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include LAPIDES ASSET MANAGEMENT, LLC (5.00%). View Institutional Ownership Trends for Trinity Biotech PLC.

How do I buy Trinity Biotech PLC stock?

Shares of Trinity Biotech PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trinity Biotech PLC's stock price today?

One share of Trinity Biotech PLC stock can currently be purchased for approximately $5.11.

MarketBeat Community Rating for Trinity Biotech PLC (NASDAQ TRIB)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trinity Biotech PLC (NASDAQ:TRIB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Trinity Biotech PLC (NASDAQ:TRIB)
Price Target History for Trinity Biotech PLC (NASDAQ:TRIB)
Analysts' Ratings History for Trinity Biotech PLC (NASDAQ:TRIB)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2016StephensDowngradeOverweight -> Equal WeightN/AView Rating Details
4/21/2016Roth CapitalReiterated RatingBuyN/AView Rating Details
10/23/2015Craig HallumDowngradeBuy -> Hold$24.00 -> $14.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Trinity Biotech PLC (NASDAQ:TRIB)
Earnings by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)
Earnings History by Quarter for Trinity Biotech PLC (NASDAQ TRIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$0.07N/AView Earnings Details
7/20/20176/30/2017$0.06$0.03$24.83 million$25.45 millionViewN/AView Earnings Details
4/27/20173/31/2017$0.03$0.01$24.24 million$23.54 millionViewN/AView Earnings Details
10/25/2016Q3$0.07$0.07$26.50 million$26.10 millionViewListenView Earnings Details
7/21/2016Q2$0.06$0.09$24.30 million$26.30 millionViewListenView Earnings Details
4/19/2016Q1$0.08$0.06$24.34 million$23.52 millionViewListenView Earnings Details
3/3/2016Q4$0.09$0.29$251.00 million$271.20 millionViewN/AView Earnings Details
10/22/2015Q3$0.09$0.10$25.40 million$27.20 millionViewListenView Earnings Details
7/28/2015Q2$0.14$0.07$26.09 million$24.26 millionViewListenView Earnings Details
4/30/2015Q115$0.17$0.17$25.93 million$25.20 millionViewN/AView Earnings Details
3/3/2015Q414$0.18$0.18$27.30 million$26.70 millionViewN/AView Earnings Details
10/23/2014Q114$0.20$0.19$27.30 million$27.20 millionViewListenView Earnings Details
7/29/2014Q413$0.20$0.18$27.00 million$26.00 millionViewN/AView Earnings Details
4/29/2014$0.19$0.18$25.48 million$25.03 millionViewN/AView Earnings Details
3/4/2014Q4$0.21$0.20ViewN/AView Earnings Details
10/17/2013Q313$0.21$0.21$24.68 million$24.10 millionViewN/AView Earnings Details
7/30/2013Q2 2013$0.20$0.21$22.03 million$21.30 millionViewN/AView Earnings Details
3/5/2013Q4 2012$0.21$0.20$21.84 million$20.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Trinity Biotech PLC (NASDAQ:TRIB)
2017 EPS Consensus Estimate: $0.26
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.04$0.04$0.04
Q2 20171$0.06$0.06$0.06
Q3 20171$0.08$0.08$0.08
Q4 20171$0.08$0.08$0.08
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Trinity Biotech PLC (NASDAQ TRIB)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Trinity Biotech PLC (NASDAQ:TRIB)
No insider trades for this company have been tracked by


Headline Trends for Trinity Biotech PLC (NASDAQ:TRIB)
Latest Headlines for Trinity Biotech PLC (NASDAQ:TRIB)
Loading headlines, please wait.



Trinity Biotech PLC (TRIB) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.